Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390675 | 1.00 | OPRK1 (0.44) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL21513242 | 0.85 | JAK2 (0.44) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL29969803 | 0.85 | JAK2 (0.44) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL14375971 | 0.82 | HRH4 (0.44) | JAK2JAK1HRH4MCHR1HRH3 | |
| SCHEMBL29968129 | 0.80 | JAK2 (0.43) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL26130781 | 0.80 | JAK2 (0.43) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL14349505 | 0.78 | HRH4 (0.41) | JAK2JAK1HRH4MCHR1HRH3 | |
| SCHEMBL26131525 | 0.78 | OPRK1 (0.43) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL29969608 | 0.78 | OPRK1 (0.43) | OPRK1JAK2JAK1JAK3HRH4 | |
| SCHEMBL1927645 | 0.78 | HDAC6 (0.49) | OPRK1JAK2JAK1JAK3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| EP-2231646-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | OPRK1 79/4885JAK2 144/4885JAK1 398/4885 |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | OPRK1 93/4885JAK2 231/4885JAK1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.